Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background. Serum levels of CA 19-9 correlate with survival among patients with pancreatic cancer treated with surgery or radiation therapy. In addition, CA 19-9 responses have been shown to predict for a better prognosis among patients with advanced disease treated with chemotherapy. The present study evaluates the predictive role of CA 19-9 pretreatment levels and response among patients treated with gemcitabine.
Methods. We retrospectively identified 28 patients with advanced pancreatic cancer and baseline elevations of CA 19-9 (>37 U/mL) who were treated with single agent gemcitabine. CA 19-9 response was defined as a ≥50% decline at any time after treatment. Survival was estimated with the Kaplan-Meier method, and curves were compared with the log-rank test.
Results. Eleven patients (39%) had a CA 19-9 response. The median survival of responding patients was longer than that of non-responding patients (13.8 vs 8 mo, p=.0272). When pretreatment CA 19-9 levels were analyzed, patients who had CA 19-9 below the median for the entire sample (1212 U/mL) lived significantly longer than patients with a CA 19-9 above the median (14.9 vs 7.4 mo, p=.0013). On multivariable analysis, pretreatment CA 19-9 level was an independent, and stronger predictor of survival (p=.0005) than CA 19-9 response (p=.0497). Other variables were not associated with survival.
Conclusions. CA 19-9 may be a useful adjunct to response evaluation is this setting. In addition to CA 19-9 responses, prechemotherapy levels of this marker seem to have strong prognostic significance.
- Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7–33. CrossRef
- Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F. Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer 1994;57:786–792. CrossRef
- Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33–64. CrossRef
- Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326(7):455–465. CrossRef
- Janes RH, Jr., Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell LH, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 1996;223(3):261–272. CrossRef
- Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996;78:654–663.
- Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996;78(3 Suppl.):627–632.
- Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403–2413.
- Safi F, Beger H, Bittner R, Buchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779–783. CrossRef
- Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987;60(10):2428–2431. CrossRef
- Glenn J, Steinberg W, Kurtzman S, Steinberg S, Sindelar W. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6(3):462–468.
- Lundin J, Roberts P, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515–519.
- Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and post-operative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9(6):735–740. CrossRef
- Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41(2):393–396.
- Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 1998;45(21):867–872.
- Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44(13):279–283.
- Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77(2):325–328.
- Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82(5):1013–1016. CrossRef
- Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481. CrossRef
- Cox DR. Regression models and life tables (with discussion). J R Statist Soc 1972;34(series B):187–220.
- Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta H, et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986;57(7):1324–1326. CrossRef
- Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumo-rassociated antigen CA19-9. Pancreas 1994;9(6):731–734. CrossRef
- Safi F, Schlosser W, Falkenreck S, Beger HG. CA 19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatol 1996;20(3):155–161.
- Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996;78(1):57–62. CrossRef
- Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996;172(4):350–352. CrossRef
- Diez M, Cerdan FJ, Pollan M, Maestro ML, Ortega MD, Martinez S, et al. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma. Anticancer Res 1994;14(6B):2819–2825.
- Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49(2):78–85. CrossRef
- Wolmark N, Fisher B, Wieand HS, Henry, RS, Lerner, H, Legault-Poisson, S, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984;199(4):375–382. CrossRef
- Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994;14:2082–2084. CrossRef
- Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16(5):1835–1843.
- Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol 2001;19(5):1304–1311.
- Rustin GJ, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989;7(11):1667–1671.
- Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17(2):501–508.
- Heinemann V, Schermuly MM, Stieber P, Schulz L, Jungst D, Wilkowski R, Schalhom A. CA19-9: a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999;19(4A):2433–2435.
- Heinemann V, Stemmler J, Schermuly M, Stieber P, Niebler K, Wilkowski R, et al. CA 19-9: an early indicator of response to chemotherapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:276a.
- Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73(1):101–105.
- Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20(5):1182–1191. CrossRef
- Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
International Journal of Gastrointestinal Cancer
Volume 32, Issue 1 , pp 35-41
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Pancreatic neoplasms
- drug therapy
- CA 19-9
- Industry Sectors
- Author Affiliations
- 1. Centro Paulista de Oncologia, Av. Europa 105, 01449-001, São Paulo, Brazil
- 2. University of São Paulo, São Paulo, Brazil